Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Ana Gonzalez‐Cordón, Juergen Rockstroh, Giovanni Guaraldi(University of Modena and Reggio Emilia), Georg M. N. Behrens(Medizinische Hochschule Hannover), Mark Gompels, Els Caluwé(Ghent University Hospital), Christine Katlama(Université Paris Cité), Clotilde Allavena(Centre Hospitalier Universitaire de Nantes), David Boutoille(Inserm), Julie Fox(National Health Service), J. Connault, Christoph Stephan(Goethe University Frankfurt), Coca Necsoi(Centre Hospitalier Universitaire de Saint-Pierre), Thierry Le Tourneau, Adriana Pinto, Elisabeth André‐Garnier, Jean‐Michel Molina(Assistance Publique – Hôpitaux de Paris), Miresta Prévilon(Délégation Paris 7), Anton Pozniak, Graeme Moyle(Chelsea and Westminster Hospital), Nadine Ktorza, Véronique Reliquet, Peré Domingo(Hospital de Sant Pau), Éric Florence(Instituut voor Tropische Geneeskunde), Linos Vandekerckhove(Ghent University Hospital), Stefan Eßer(Essen University Hospital), Mar Masiá(Universidad de Alcalá), Estebán Martínez(Instituto de Salud Carlos III), Laura Waters(Central and North West London NHS Foundation Trust), Maartje Van Frankenhuijsen, Lambert Assoumou(Inserm), Margaret Johnson(Duke University), François Raffi(Centre Hospitalier Universitaire de Nantes), Véronique Joly(ViiV Healthcare (United Kingdom)), Yazdan Yazdanpanah(Inserm), Roland Landman, Luminita Schneider, Gundolf Schüttfort, José M. Gatell(Hospital Clínic de Barcelona), Hans‐Jürgen Stellbrink, Audrey Rodallec, Morane Cavellec, Samuel Ferret, Fabienne Caby, Timo Wolf(Goethe University Frankfurt)
Journal of Antimicrobial Chemotherapy
April 28, 2021
Cited by 27


Related Papers